Digital Biology Market Report 2026

The digital biology market size has grown rapidly in recent years. It will grow from $15.97 billion in 2025 to $18 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to increasing availability of high-throughput biological data, expansion of genomic sequencing activities, growth of bioinformatics research initiatives, rising adoption of laboratory automation, improvements in computational processing power.

The digital biology market size is expected to see rapid growth in the next few years. It will grow to $29.37 billion in 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to increasing investments in ai-enabled drug discovery, expansion of personalized medicine research, growing use of digital biology in agriculture and environment studies, rising demand for scalable cloud bio platforms, increasing collaboration between tech and life sciences firms. Major trends in the forecast period include increasing adoption of computational biology platforms, rising use of AI-driven biological modeling, growing integration of multi-omics data analysis, expansion of cloud-based bioinformatics solutions, enhanced focus on digital twin biology.

The surge in healthcare research and development (R&D) expenditure is expected to drive the growth of the digital biology market in the coming years. Healthcare R&D refers to organized efforts to create, test, and improve medical treatments, devices, and procedures to enhance health outcomes and patient care. Spending on healthcare R&D is increasing due to growing demand for innovative treatments and advanced therapies, as companies invest in developing new drugs, medical devices, and personalized medicine solutions that address complex and emerging health challenges. This investment in R&D supports digital biology by funding the development of advanced computational tools and bioinformatics platforms, enabling faster analysis of biological data and more precise disease modeling to improve diagnostics and treatments. For example, in June 2025, the Department for Science, Innovation and Technology, a UK-based government ministry, announced a $114.38 billion (£86 billion) investment over four years to support science and technology research and development, including drug development, with annual spending of $29.93 billion (£22.5 billion). Consequently, the increase in healthcare R&D expenditure is propelling the growth of the digital biology market.

Leading companies in the digital biology market are increasingly adopting artificial intelligence (AI) to accelerate drug discovery and predictive biology. AI enables faster identification of therapeutic targets, optimizes drug development, and supports the creation of precise, patient-specific treatments. For instance, in December 2024, GenBio AI, a US-based digital biology company, launched Phase 1 of the AI-Driven Digital Organism (AIDO) platform. This innovative system allows comprehensive modeling of DNA, RNA, protein, and single-cell expression, providing researchers with advanced tools to simulate biological systems and accelerate medical research, drug discovery, and the development of personalized therapies.

In January 2025, Merck, a Germany-based pharmaceutical and life sciences company, acquired HUB Organoids Holding B.V. for an undisclosed amount. This acquisition expands Merck’s next-generation biology portfolio, enhancing its capabilities in advanced organoid platforms and next-generation biology tools to accelerate research and innovation in drug discovery and personalized medicine. HUB Organoids Holding B.V., based in the Netherlands, specializes in developing advanced organoid platforms and next-generation in vitro models.

Major companies operating in the digital biology market are Thermo Fisher Scientific, Illumina Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Perkin Elmer, Agilent Technologies Inc., BGI Genomics Co. Ltd., DNAnexus Inc., Seven Bridges Genomics Inc., GenBio Inc., Evogene Ltd., Cradle B.V., Ginkgo Biosecurity, Evolutionary Scale Inc., Naturannova S.A., Nexco Analytics Inc., Latent Labs Inc., BioLizard NV, Lamin Labs Inc., LatchBio Inc., Standard BioTools Inc., Recursion Pharmaceuticals Inc., Insilico Medicine Inc., Deep Genomics Inc., Valo Health Inc., LabGenius Ltd., Arzeda Corp., e-Therapeutics plc, Bio-Map, A-Alpha Bio Inc., Eikon Therapeutics Inc., Proscia Inc., Lifebit Biotech Ltd., Genestack Ltd., Seqera Labs SL, Sciepot, Pluto Biosciences Inc., SciNote LLC, Qlucore AB, 10x Genomics Inc., Bruker Corporation, Bio-Techne Corporation, Resolve Biosciences GmbH, RareCyte Inc., Oxford Nanopore Technologies plc, PacBio, Ultima Genomics Inc., Element Biosciences Inc., Benchling Inc., and Synthace Ltd.

North America was the largest region in the digital biology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital biology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the digital biology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the digital biology market by increasing costs of imported laboratory instruments, sequencing equipment, high-performance computing hardware, and specialized electronic components. Research institutions and pharmaceutical companies in North America and Europe are most impacted due to reliance on advanced imported hardware, while Asia-Pacific faces cost pressures on equipment exports. These tariffs raise capital expenditure for digital biology infrastructure and may slow hardware upgrades. However, they also encourage domestic manufacturing of lab equipment, greater use of cloud-based solutions, and software-centric innovation that reduces dependency on imported physical assets.

The digital biology market research report is one of a series of new reports that provides digital biology market statistics, including digital biology industry global market size, regional shares, competitors with a digital biology market share, detailed digital biology market segments, market trends and opportunities, and any further data you may need to thrive in the digital biology industry. This digital biology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The digital biology market involves the use of computational tools, digital technologies, and advanced laboratory systems to model, simulate, and analyze biological processes at molecular, cellular, and organismal levels. By converting biological data into digital formats, it enables precise understanding, experimentation, and innovation across various life sciences applications.

The main components of digital biology include software, hardware, and services. Digital biology software consists of computer programs and platforms that model, simulate, analyze, and interpret biological systems using computational methods. Deployment modes include on-premises and cloud-based systems, leveraging technologies such as artificial intelligence in biology, bioinformatics tools, blockchain for data integrity, cloud computing solutions, and DNA data storage technology. Applications span drug discovery, agriculture, environmental monitoring, personalized medicine, synthetic biology, bioinformatics, and more, serving pharmaceutical and biotechnology companies, research and academic institutes, healthcare providers, contract research organizations, and government and regulatory bodies.

The digital biology market consists of revenues earned by entities by providing services such as bioinformatics services, genomic sequencing and analysis, and molecular diagnostics support. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital biology market also includes of sales of bioinformatics platforms, biological database subscriptions, synthetic biology design tools, laboratory automation instruments, and high-performance computing systems for biological research. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.